Timeline of major phase 3 clinical trials of first-line treatments for advanced hepatocellular carcinoma by year of publication or presentation at a national meeting.
HAIC, hepatic arterial infusion chemotherapy; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TTP, time to progression.
aMedian survival not yet reached. Results reported are after a median follow-up of 8.6 months.